<DOC>
	<DOCNO>NCT00418756</DOCNO>
	<brief_summary>This study evaluate effect 600 mg daily oral dose rifampin ( CYP3A4 inducer ) pharmacokinetics single 400 mg oral dose nilotinib healthy subject</brief_summary>
	<brief_title>Effects Rifampin Pharmacokinetics Nilotinib Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Rifampin</mesh_term>
	<criteria>1 . Healthy adult male ( 18 55 yr ) sterile post menopausal female subject : 2 . Body weight must â‰¥50 kg &lt; 100 kg , body mass index ( BMI ) &gt; 18 &lt; 33 . 1 . Female pregnant , test positive serum pregnancy test currently breast feed . 2 . Contraindication receive nilotinib rifampin . 3 . Smokers use tobacco product product contain nicotine last 30 day 4 . A past medical history clinically significant Electrocardiogram abnormality , history/family history long QTinterval syndrome . Other protocoldefined inclusion/exclusion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>nilotinib</keyword>
	<keyword>Rifampin</keyword>
	<keyword>PK</keyword>
	<keyword>healthy subject</keyword>
</DOC>